

---

## News Release

---

September 2, 2022

Sumitomo Pharma Co., Ltd.

### **Sumitomo Pharma Announces Personnel Changes**

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following personnel changes:

#### **Changes in Personnel (effective October 1, 2022)**

##### Drug Research (Division)

| Position as of October 1, 2022                     | Current position   | Name               |
|--|--|--------------------|
| Senior Project Director, Early-phase Drug Research | Senior Director, Platform Technology Research Unit         | Hidetaka Nagata    |
| Senior Project Director, Late-phase Drug Research  | Director, Pharmacology Group I, Pharmacology Research Unit | Taro Kato          |
| Senior Director, Platform Technology Research Unit | Senior Project Director, Early-phase Drug Research         | Masakazu Hashimoto |

##### Drug Development (Division)

| Position as of October 1, 2022  | Current position                                   | Name             |
|---|--|------------------|
| Senior Director, Development Planning & Management<br>Senior Director, Oncology Clinical Development Unit | Senior Director, Development Planning & Management | Katsunori Maruta |

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5205-3725 (Tokyo)